High doses of tigecycline are associated with satisfactory plasmatic and pulmonary concentrations for the treatment of severe infections due to fully susceptible bacteria: do we need even higher doses in patients under CRRT?
Crossref DOI link:
Update policy: https://doi.org/10.1007/SPRINGER_CROSSMARK_POLICY
Honore, Patrick M.
Barreto Gutierrez, Leonel
De Bels, David
Text and Data Mining valid from 2020-10-14
Version of Record valid from 2020-10-14
13 August 2020
6 October 2020
14 October 2020
Ethics approval and consent to participate
The authors declare to have no competing interests.